Cancer Letters

Cancer Letters

Volume 103, Issue 1, 15 May 1996, Pages 1-9
Cancer Letters

Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma

https://doi.org/10.1016/0304-3835(96)04178-XGet rights and content

Abstract

The mechanisms whereby tumors escape immunosurveillance remain poorly understood. De-activation or deviation of T lymphocyte responses may occur following exposure to tumor-associated or -derived signals. In the present study it is demonstrated that during development of syngeneic malignant mesothelioma in mice, the relative CD3δ, CD3γ and CDη mRNA levels expressed by tumor infiltrating lymphocytes (TIL) decrease, while CD3ε mRNA levels remain relatively constant. Expression of IFNγ mRNA by TIL decreased during tumor development, while IL-2 mRNA levels showed slight increases. IL-3 mRNA was not detected at any time during tumor development and IL-4 transcripts were only detected in the later stages of tumor development. In the spleens of tumor-bearing mice, IL-2 transcripts were detected throughout the time course from days 1 to 22(24), while IFNγ mRNA was only detected at early times from days 0–13. Previous work demonstrated a role for tumor cell-derived TGFβ in the immunobiology of mesothelioma. Here it is shown that the suppression of CD3-subunit expression by TIL was ameliorated in tumors where TGFβ-expression was reduced by inducible TGFβ-specific antisense-RNA, thus, suggesting that lymphocytes may become de-activated upon infiltration of the tumor micro-environment.

References (33)

  • E. Kedar et al.

    Cancer immunotherapy: are the results discouraging? Can they be improved?

    Adv. Cancer Res.

    (1992)
  • H. Bielefeldt-Ohmann et al.

    The potential for interferon-α based therapy in mesothelioma: assessment in a murine model

    J. Interferon Cytokine Res.

    (1995)
  • H. Bielefeldt-Ohmann et al.

    Interleukin-6 involvement in mesothelioma: inhibition by interferon-α immunotherapy

    Cancer Immunol. Immunother.

    (1995)
  • H. Bielefeldt-Ohmann et al.

    Patho- and immunobiology of malignant mesothelioma: characterisation of tumor infiltrating leukocytes and cytokine production in a murine model

    Cancer Immunol. Immunother.

    (1994)
  • R.P. Bucy et al.

    Heterogeneity of single cell cytokine gene expression in clonal T cell populations

    J. Exp. Med.

    (1994)
  • M. Buferne et al.

    Role of CD3δ in surface expression of the TCR/CD3 complex and in activation for killing analyzed with a CD3δ-negative cytotoxic T lymphocyte variant

    J. Immunol.

    (1992)
  • L.K. Clayton et al.

    CD3η and CD3ζ are alternatively spliced products of a common genetic locus and are transcriptionally and/or post-transcriptionally regulated during T-cell development

  • H. Clevers et al.

    The T cell receptor/CD3 complex: a dynamic protein ensemble

    Annu. Rev. Immunol.

    (1988)
  • R. de Jong et al.

    Differential effect of transforming growth factor-β1 on the activation of human naive and memory CD4+ T lymphocytes

    Intern. Immunol.

    (1994)
  • D.R. DeSilva et al.

    Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation

    J. Immunol.

    (1991)
  • J.R. Doskow et al.

    CD3-γ, -δ, -ξ, T-cell receptor-α and -β transcripts are independently regulated during thymocyte ontogeny and T-cell activation

    Immunology

    (1992)
  • F. Farace et al.

    The decreased expression of CD3ζ chains in cancer patients is not reversed by IL-2 administration

    Int. J. Cancer

    (1994)
  • C. Fargens et al.

    Differential effect of TGFβ on the synthesis of TH1 and TH2-like lymphokines by human T lymphocytes

    Eur. J. Immunol.

    (1992)
  • J.H. Finke et al.

    Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma

    Cancer Res.

    (1993)
  • D.R. Fitzpatrick et al.

    Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and T-cell infiltration in malignant mesothelioma

    Growth Factors

    (1994)
  • D.R. Fitzpatrick et al.

    The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma

    Am. J. Resp. Cell Mol. Biol.

    (1995)
  • Cited by (34)

    • Intracavitary Therapeutics for Pleural Malignancies

      2013, Clinics in Chest Medicine
      Citation Excerpt :

      Immunotherapy has been attempted in MM, despite observations of a significant immunosuppressive tumor microenvironment.20–22 In addition to the tumor’s innate mechanisms of immune evasion, patients with MM have impaired immune systems: abnormal humoral and cell-mediated immunity, abnormal cell-mediated antibody-dependent cellular toxicity, and defective macrophage and natural killer (NK) cell function.22–25 However, high local levels of certain proinflammatory cytokines may be able to overcome the innate immune resistance of MM.

    View all citing articles on Scopus
    View full text